# A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

> **NCT01235559** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 604 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** bitopertin [RO4917838] level 1
- **DRUG:** bitopertin [RO4917838] level 2

## Key facts

- **NCT ID:** NCT01235559
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235559, "A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01235559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*